<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00464594</url>
  </required_header>
  <id_info>
    <org_study_id>JEDIS ver.4.0</org_study_id>
    <secondary_id>UMIN000000681</secondary_id>
    <nct_id>NCT00464594</nct_id>
  </id_info>
  <brief_title>Japan Early Diabetes Intervention Study</brief_title>
  <acronym>JEDIS</acronym>
  <official_title>A Randomized Comparative Clinical Study on Suppression of Progression From Early Diabetes, Diet/Exercise Standard Intervention vs. Concurrent Pharmacological Standard Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Early Diabetes Intervention Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Japan Early Diabetes Intervention Study Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the suppressive effect of two kinds of interventions&#xD;
      on the worsening/progression to definite diabetes: standard lifestyle guidance and standard&#xD;
      lifestyle guidance combined with pharmacological intervention (monotherapy with one of&#xD;
      acarbose, metformin, or gliclazide).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In newly-diagnosed early diabetes patients, a randomized comparative study will be conducted&#xD;
      to compare the suppressive effect of the following two kinds of interventions on the&#xD;
      worsening/progression to definite diabetes which has a harmful hyperglycemia i.e. an&#xD;
      increased risk of microangiopathy: standard education for the improvement of lifestyle in&#xD;
      accordance with the &quot;Guidelines for the Treatment of Diabetes Mellitus in Japan&quot; of the Japan&#xD;
      Diabetes Society (JDS) and standard lifestyle guidance combined with pharmacological&#xD;
      intervention using the lowest possible dose of commercially available oral hypoglycemic&#xD;
      agents (one of acarbose, metformin, or gliclazide) in Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FPG &gt;= 140mg/dl and HbA1c &gt;= 7.0%</measure>
  </primary_outcome>
  <enrollment>2560</enrollment>
  <condition>Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Standard lifestyle guidance</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with acarbose</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with metformin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifestyle guidance and monotherapy with gliclazide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Results of 75-g oral glucose tolerance test (75 g OGTT)will be used to confirm FPG &lt;=&#xD;
             125 mg/dL, 2-h PG &gt;= 200 mg/dL and HbA1c &lt;= 6.9%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Undergoing treatment with steroids&#xD;
&#xD;
          -  Secondary diabetes mellitus&#xD;
&#xD;
          -  Diabetes mellitus due to suspected gene abnormalities&#xD;
&#xD;
          -  BMI &gt;= 35 kg/m2 or BMI &lt; 18.5 kg/m2&#xD;
&#xD;
          -  Undergone a surgery&#xD;
&#xD;
          -  Severe hyperuricemia (gout) associated with organ dysfunction&#xD;
&#xD;
          -  Severe vascular diseases with organ dysfunction&#xD;
&#xD;
          -  Cancer or other malignant neoplasms&#xD;
&#xD;
          -  Liver cirrhosis or chronic hepatic, chronic renal failure&#xD;
&#xD;
          -  Gastrointestinal disorders&#xD;
&#xD;
          -  Always performing rigorous muscular exercise&#xD;
&#xD;
          -  Severe infection or serious trauma&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Alcohol dependence or drug dependence&#xD;
&#xD;
          -  Drug allergy&#xD;
&#xD;
          -  Anemic&#xD;
&#xD;
          -  Abnormal hemoglobinuria&#xD;
&#xD;
          -  Severe mental disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kuzuya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jichi Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazuo Ichikawa</last_name>
    <phone>81-3-3814-8010</phone>
    <email>info@jedis2560.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tokyo Medical and Dental University</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>03-3813-6111</phone>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 19, 2007</study_first_submitted>
  <study_first_submitted_qc>April 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2007</study_first_posted>
  <last_update_submitted>April 22, 2007</last_update_submitted>
  <last_update_submitted_qc>April 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2007</last_update_posted>
  <keyword>Japan Early Diabetes Intervention Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

